分析台灣生技新藥研發產業-以中裕新藥為例

Abstract

瑞士一個人口不到台灣一半的國家，擁有世界上兩大藥廠座落分別是Novartis與Roche，據研究該成功因素有賴於資本市場的健全與國家中立立場，而兩大藥廠，亦均專注於處方簽藥物（研發投入高）等癌症藥品。而本研究的個案公司–中裕新藥(前身為宇昌生技)，其所專注研發的藥物TMB-355 針對愛滋病(HIV 病毒)治療獲得孤兒藥、突破性療法雙重認可，其前景可期。在該公司創建初期，即2007年9月，亦為生技新藥產業條例初始階段，公司隨著政策的浪潮，尋求更多展望。中裕新藥可說是台灣生技產業在新藥研發上代表性的企業。至此，本研究透過Michael E. Porter 所提出的五力分析，探討產業關鍵要素，並透過基礎資源觀點盤點中裕新藥資源與能力，進一步明白中裕新藥競爭力的來源為何與是否能持續。最後透過分析公司經營與發展策略，得知中裕新藥在新藥研發的脈絡與未來可能發展。至今中裕新藥依時間軸其發展為:聚集技術人才、取得資源打破進入障礙、透過劑型的布局與藉由孤兒藥、突破性療法加速上市。中裕新藥雖掌握到本研究羅列出關鍵要素的能耐，即技術人力、研發時間、環境因素、產品劑型等。然而，最後在中裕新藥極可能上市的情況下，給予本研究建議，分別是:密切注意銷售情形、產品過於仰賴標竿藥物、與思索被併購的可能。另外藉中裕新藥針對孤兒藥的市場抓取給予台灣新藥研發產業一個發展的案例先鋒。

Switzerland's population is less than half of Taiwan, but it has two of the world's largest pharmaceutical companies which are Novartis and Roche. According to the study of Switzerland, it is successful because of perfect capital market and national neutral position. Both of the pharmaceutical companies are focused on prescription drugs (high R & D investment) and other cancer drugs. The company in this research, TaiMed Biologics (formerly known as Yuchang biotechnology) is focus on drugs TMB-355 for AIDS (HIV) treatment. TMB-355 also earned Orphan Drugs and Breakthrough Therapy Designation. Therefore, investors think it is profitable. September 2007, TaiMed Biologics was created. At the same time, it is also set the stage for Taiwan’s biotechnology industry take-off. TaiMed Biogics enterprise could be said the benchmark of Taiwan’s biotechnology industry in the new drug research and development. In this research, we use Michael E. Porter proposed five force analysis, to explore the key elements of the industry, and through Resource-Based View, to find company’s resources and ability. Next, we analyze TaiMed Biogics competitiveness and its sustainability. Finally, we conclude that TaiMed Biogics is on the right path after the analysis of the company’s business and development strategy. So far, TaiMed Biogics has followed this chronological development: gathered technical talents, broke industry barriers, completed pharmacy pattern layout, accelerated going to the market by Orphan Drugs and Breakthrough Therapy Designation. In the end, we give some advice to the future of TaiMed Biogics: (1) pay more attention to the sales, (2) do not be too dependent on benchmarking drugs, (3) think about the possibility of M&A. In addition, TaiMed Biogics in Orphan Drug’s experience could be a pioneer in the development case.